Clinical Study
Testing the Study Drug Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis
Eosinophilic esophagitis is a disease that affects the lining of the tube between your mouth and stomach. This study will test a drug called Barzolvolimab (CDX-0159) in adults with this disease. The study wants to see if the drug will help people with the disease and is safe. People in this study will be randomly chosen to be treated with doses of Barzolvolimab (CDX-0159) and placebo. The drug and placebo are taken as a swallowed pill. A placebo is a pill that does not have the drug. Being in the study requires up to 50 weeks at the clinic. Medical tests will be done during the study to track the health of participants.
For more information contact:
Amy Nichols
amy.nichols@hsc.utah.edu
801-581-7802
IRB#: IRB_00170529
| PI: Kathryn Peterson
| Department: INTERNAL MEDICINE
| Approval Date: 2023-09-27 06:00:00
Specialties: Gastroenterology
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 years to 80 years old
- Diagnosis and symptoms of Eosinophilic esophagitis
- Participants of childbearing age willing to use birth control
- Able to attend in person at a study clinic
Exclusion Criteria:
- History of other specific diseases such as Crohns
- Severe or uncontrolled chronic diseases such as diabetes and heart disease that impact participation
- Avoid solid foods or use a feeding tube
- Active chronic or severe infection requiring treatment such as antibiotics
- Prior use of Barzolvolimab (CDX-0159)
Will I be paid for my time?
Yes